

COMPANY OVERVIEW

VistaGen Therapeutics (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, with emphasis on major depressive disorder, neuropathic pain, Parkinson's disease LID, social anxiety disorder and suicidal ideation.

VistaGen's AV-101, an oral NMDAR GlyB antagonist, belongs to a new generation of investigational medicines in neuropsychiatry known as glutamate receptor modulators with the potential to treat major depressive disorder faster and with fewer side effects than currently available FDA-approved antidepressants which, if effective, often take many weeks to months to achieve therapeutic benefits and are associated with side effects and safety concerns. With at-home convenience of an oral therapy, AV-101 has the potential to drive a paradigm shift towards a new generation of safer and faster-acting antidepressants. The FDA has granted Fast Track designation to AV-101 for development as an adjunctive treatment for major depressive disorder and as a non-opioid treatment of chronic neuropathic pain.

VistaGen's PH10 and PH94B were developed from proprietary compounds called pherines. With intranasal administration, PH10 and PH94B act locally on peripheral nasal chemosensory receptors that trigger rapid activation of neural impulses in areas of the brain associated with depression (PH10) social anxiety disorder (PH94B). This mechanism of pharmacological action, the rapid onset of efficacy, and the excellent safety and tolerability profile demonstrated in clinical trials to date make PH10 and PH94B, respectively, excellent product candidates for chronic treatment of patients with depression and for on-demand (PRN) treatment of social anxiety disorder.

RECENT NEWS

VistaGen Therapeutics Receives AV-101 Japanese Patent for Treatment of Depression and Hyperalgesia

Feb 19 2019, 8:30 AM EST

STOCK OVERVIEW

Symbol	VTGN
Exchange	Nasdaq
Market Cap	42.95m
Last Price	\$1.38
52-Week Range	\$0.8101 - \$2.44

02/22/2019 04:00 PM EST

INVESTOR RELATIONS

VistaGen Therapeutics, Inc.
Mark A. McPartland
Vice President, Corporate
Development
(650) 577-3606
markmcp@vistagen.com
KCSA Strategic Communications
Valter Pinto / Allison Soss
(212) 896-1254 / (212) 896-1267
VistaGen@KCSA.com

MANAGEMENT TEAM

Shawn K. Singh

Chief Executive Officer and Director

H. Ralph Snodgrass, Ph.D.

Founder, President, Chief Scientific Officer and Director

Mark A. Smith, M.D., Ph.D.

Chief Medical Officer

Jerrold D. Dotson, CPA

Vice President, Chief Financial Officer and Secretary

Mark A. McPartland

Vice President of Corporate Development

VISTAGEN THERAPEUTICS, INC.

343 Allerton Avenue
South San Francisco, CA 94080

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive

factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.